The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS
Open accessAbstract
Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P < .001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; P < .001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; P < .001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P = .014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P = .011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GLP-1 analogs are being investigated as disease-targeted therapies with the potential to slow the progression of cognitive decline.
“Glucagon‐like peptide 1 (GLP‐1) analogs are being investigated as disease‐targeted therapies with the potential to slow the progression of cognitive decline. 34 , 35 , 36 , 37”
From Critical evaluation of real‐world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation (2026) · cites this paper as [35]
The Discussion says GLP-1 receptor agonists may have neuroprotective activity, and the Conclusion reports a lower associated risk of developing Alzheimer disease in patients with type 2 diabetes. Neither section establishes that these drugs are being investigated as disease-targeted therapies to slow the progression of existing cognitive decline; the study examined reported adverse events, not cognitive progression. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 1×
“Another hypothesis pertaining to AD pathology is the so-called tau hypothesis.(7) Under normal conditions, tau acts to stabilize microtubules and control intracellular trafficking.”
BackgroundDifferential Regulation of Dynein and Kinesin Motor Proteins by Tau
Dixit, R., Ross, J. L., Goldman, Y. E., & Holzbaur, E. L. F. (2008) · Science · doi:10.1126/science.1152993 · Cited by 1,012
Phosphorylation affects the ability of tau protein to promote microtubule assembly.
Lindwall, G., & Cole, R. D. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42989-9 · Cited by 901
Diabetes mellitus and risk of dementia: A meta‐analysis of prospective observational studies
Gudala, K., Bansal, D., Schifano, F., & Bhansali, A. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12087 · Cited by 727
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Ricciarelli, R., & Fedele, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170116143743 · Cited by 380
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Vagelatos, N. T., & Eslick, G. D. (2013) · Epidemiologic Reviews · doi:10.1093/epirev/mxs012 · Cited by 320
Campbell, J. M., Stephenson, M. D., de Courten, B., Chapman, I., Bellman, S. M., & Aromataris, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180263 · Cited by 292
A curated and standardized adverse drug event resource to accelerate drug safety research
Banda, J. M., Evans, L., Vanguri, R. S., Tatonetti, N. P., Ryan, P. B., & Shah, N. H. (2016) · Scientific Data · doi:10.1038/sdata.2016.26 · Cited by 246
Hamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227
Flagged first, then by citations
Research works printed but not linked: 43
- 10.1016/j.jalz.2017.10.009 · DOI · Paper page
- 10.1016/S0196-9781(02)00063-3 · DOI
- 10.1126/science.1566067 · DOI · Paper page
- 10.1073/pnas.0607919104 · DOI · Paper page
- Grundke-Iqbal I, 1986, J Biol Chem, 261, 6084, 10.1016/S0021-9258(17)38495-8 · DOI
- 10.3233/JAD-170440 · DOI
- 10.1007/s12035-012-8339-9 · DOI
- 10.1002/path.2912 · DOI
- 10.1111/dom.12123 · DOI · Paper page
- 10.1370/afm.214 · DOI
- 10.7326/M15-2650 · DOI · Paper page
- 10.7326/M15-3016 · DOI
- 10.1001/jama.2009.460 · DOI · Paper page
- 10.1001/jamainternmed.2013.6176 · DOI
- 10.1161/01.STR.0000199613.38911.b2 · DOI
- 10.1016/S1734-1140(10)70357-1 · DOI
- 10.1016/j.neuropharm.2015.07.023 · DOI
- 10.2337/dc10-0389 · DOI
- Zhong Y, 2012, Biomed Environ Sci, 25, 1
- 10.3233/JAD-141521 · DOI
- 10.1210/jc.2017-00439 · DOI
- Shorr RI, 2006, J Nutr Health Aging, 10, 297
- 10.1007/s00125-009-1323-x · DOI · Paper page
- 10.1111/j.1463-1326.2007.00832.x · DOI
- 10.1016/S0140-6736(08)61246-5 · DOI · Paper page
- 10.1097/MJT.0b013e3182204c16 · DOI
- 10.1038/sj.ijo.0802206 · DOI
- 10.2337/dc13-2759 · DOI · Paper page
- 10.1111/j.1476-5381.2012.01971.x · DOI
- 10.1016/j.bbadis.2013.01.008 · DOI
- 10.2147/PPA.S151736 · DOI
- 10.18632/oncotarget.22467 · DOI
- 10.1007/s12640-017-9784-z · DOI
- 10.1111/bph.13378 · DOI
- 10.1016/S0149-2918(02)85040-8 · DOI
- Sharma SK, 2016, J Assoc Physicians India, 64, 24
- Watson GS, 2005, Am J Geriatr Psychiatry, 13, 950
- 10.2165/11587580-000000000-00000 · DOI
- 10.18553/jmcp.2016.22.5.483 · DOI
- 10.1592/phco.27.8.1102 · DOI
- 10.1055/s-0035-1559608 · DOI
- 10.1111/dom.13086 · DOI · Paper page
- 10.14740/jocmr2540w · DOI
Cited by
Sorted by citations
Cummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., Johannsen, P., León, T., & Scheltens, P. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01666-7 · Cited by 168
Wu, C.-Y., Iskander, C., Wang, C., Xiong, L. Y., Shah, B. R., Edwards, J. D., Kapral, M. K., Herrmann, N., Lanctôt, K. L., Masellis, M., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1705 · Cited by 139
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
Extending the Nested Model for User-Centric XAI: A Design Study on GNN-based Drug Repurposing
Wang, Q., Huang, K., Chandak, P., Zitnik, M., & Gehlenborg, N. (2023) · IEEE Transactions on Visualization and Computer Graphics · doi:10.1109/tvcg.2022.3209435 · Cited by 82
Rhea, E. M., Babin, A., Thomas, P., Omer, M., Weaver, R., Hansen, K., Banks, W. A., & Talbot, K. (2024) · Tissue Barriers · doi:10.1080/21688370.2023.2292461 · Cited by 81
Tian, S., Jiang, J., Wang, J., Zhang, Z., Miao, Y., Ji, X., & Bi, Y. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3673 · Cited by 79
Tonegawa‐Kuji, R., Karavani, E., Danziger, M., Zhang, P., Hou, Y., Zhou, Y., Bykova, M., Pieper, A. A., Rosen‐Zvi, M., Cummings, J., et al. (2026) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.70193 · Cited by 1
Metadata
- Authors
- Akimoto, H., Negishi, A., Oshima, S., Wakiyama, H., Okita, M., Horii, N., Inoue, N., Ohshima, S., & Kobayashi, D.
- Affiliations
- Josai University (JP)
- Corresponding author
- Oshima, Shinji
- ORCID
- Venue
- American Journal of Alzheimer's Disease & Other Dementias®
- Publisher
- SAGE Publications
- Published
- 2020-01-01
- Volume
- 35
- Pages
- 1533317519899546-1533317519899546
- ISSN
- 0888-4897 (ISSN-L)
- 1533-3175
- 1938-2731
- PMC
- PMC11005324
- OpenAlex
- W3011560571
- Cited by
- 89
- References
- 15
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 16 · 2023: 15 · 2022: 17 · 2021: 7 · 2020: 1
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- American Journal of Alzheimer s Disease & Other Dementias® (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- Alzheimer's disease, type 2 diabetes, antidiabetic drugs, drug safety, adverse drug reactions, rosiglitazone, exenatide, liraglutide, dulaglutide, sitagliptin, metformin, GLP-1 receptor agonists, elderly patients
- MeSH terms
- Liraglutide, Exenatide, Aged, Alzheimer Disease, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Metformin, Recombinant Fusion Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
